Day: August 21, 2024

SHANGHAI, China, Aug. 21, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial HighlightsNet revenue increased by 14.3% year-over-year (“Y-o-Y”) to RMB2,826.4 million (US$388.9 million) in the second quarter of 2024 (2Q2023: RMB2,472.0 million). Net revenue increased by 17.7% Y-o-Y in the second quarter of 2024 (excluding previously disclosed one-time items of RMB70.7 million from the same period last year). Net loss was RMB231.8 million (US$31.9 million) in the second quarter of 2024 (2Q2023: net loss of RMB225.3 million). Adjusted EBITDA (non-GAAP) increased...

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conference: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Wednesday, September 4, 2024, at 7:45 a.m. ETLocation: Marriott Marquis in New York, NYFormat: Fireside Chat A live webcast of the Fireside Chat will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days. About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming...

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) — Copper Road Resources Inc. (TSXV: CRD) (“Copper Road” or the “Company”) is pleased to announce to announce a fully subscribed non-brokered private placement (the “Offering”) for gross proceeds of $100,000 from the sale of 5,000,000 common shares of the Company. The closing of the Offering is expected to occur on or about September 5, 2024, and is subject to receipt of all necessary regulatory approvals including the TSX Venture Exchange (“TSXV”). The Company expects to use the proceeds for exploration activities on the Mount Jamie property and for general working capital purposes. About Copper Road Copper Road Resources (TSXV: CRD) is a Canadian based explorer engaged in the acquisition, exploration and evaluation of properties for the mining of precious and base metals. For more information,...

Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. “We...

TAMPA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) — CTT Pharmaceuticals Holdings, Inc. (OTC: CTTH), is pleased to announce that the registered PCAOB Accounting Firm of DiPiazza, LaRocca, Heeter & Co., led by audit partner Matthew Stewart have successfully completed the 2 year audit of CTT Pharma. This comprehensive audit included the review of CTT’s bank statements, patents, contracts and share allocation over the past 2 years and has received the necessary approvals to allow CTT Pharma to be in compliance with PCAOB Regulations. The PCAOB Audit Letter and Audited Financials for 2022 and 2023 have been successfully uploaded to the OTC Markets Website for anyone to view. This important milestone will allow CTT to uplist at any point now and should also give existing shareholders, future shareholders, investment firms and potential...

Total Revenues Reach US$5.1 MillionGross Profit Increases by 9.4% to US$1.7 MillionNet Income of US$0.1 million BANGKOK, Thailand, Aug. 21, 2024 (GLOBE NEWSWIRE) — NewGenIvf Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that on August 19, 2024, the Company filed its 2023 annual report (20-F) with the SEC. 2023 Financial HighlightsTotal revenues were US$5.1 million in the full year of 2023. Gross profit increased by 9.4% to US$1.7 million from US$1.5 million in the full year of 2022. Gross margin was 32.8%, compared to 25.9% in the full year of 2022. Net income was US$0.1 million in the full year of 2023.Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, “2023 was...

Patented personalized medicine approach for patient dosing for autologous cell therapy Expected to meaningfully enhance clinical experience and market opportunitySUNNYVALE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the FDA has approved a protocol amendment for the CardiAMP Heart Failure II Trial, BioCardia’s confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF). The protocol amendment allows patients who would have previously been excluded from treatment to receive additional cell deliveries to achieve the same target minimum dosage utilizing a treatment...

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes Clinical Proof-of-Concept for Disease-Modifying Potential of CM-101 and Provides Foundation for Advancing to PSC Phase 3 Pivotal Trial── ──Completed PIPE Financing Including Major New and Existing Investors that Extends Cash Runway Through Beginning of 2026── ──On Track to Achieve Key Clinical Milestones in First Quarter of 2025; Continuing Discussions with Potential Partners── TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial...